ClinicalTrials.gg
Not yet recruitingNCT07359963Updated Jan 22, 2026

Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy

An Early Phase 1 interventional study of REGEND007 Cell Therapy in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Regend Therapeutics. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Regend Therapeutics · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
54th of 60
12 · median 83
Started
2026
with 12 others
Phase 1
20 of 67
5 open now
Primary completion
2027-02
later than 11 of 28 live
Registered
56th of 67
by date
Lead sponsor
3 of 67
Regend Therapeutics

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 54th largest by planned enrollment of the 60 interventional ones that give a count, is one of 13 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 11 of the 28 other live ones, and was the 56th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gender is not restricted. When signing the form, the age should be between 40 and 80 years old (inclusive of the boundary value).
  • Diagnosed with idiopathic pulmonary fibrosis (IPF).
  • During the screening process, the six-minute walk test should be ≥ 150 meters and \< 600 meters; or the lung function FVC should be > 30% of the predicted value.
  • Voluntarily sign the informed consent form, be able to cooperate with the completion of research-related procedures and examinations, and be able to comprehensively describe or record the changes in the condition.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, breastfeeding, or planning to become pregnant within one year after using this product; or male subjects whose partner is planning to become pregnant.
  • Subjects selected during the screening whose estimated survival period is less than one year.
  • Subjects selected during the screening who have a current or past history of malignant tumors (excluding malignant tumors with a disease-free survival of more than five years and judged by the researcher to have a relatively mild invasiveness, such as non-melanoma skin cancer, invasive cervical cancer, bladder cancer, thyroid cancer, and breast cancer, etc.).
  • Subjects selected within 4 weeks before diagnosis of pneumonia (including bacterial, fungal or viral pneumonia).
  • Subjects selected within 4 weeks before an acute exacerbation of IPF.
  • Subjects selected within 4 weeks before having one or more results reported by pathogenological or serological tests (nucleic acid, antigen, virus culture, specific IgG antibody levels) indicating novel coronavirus infection, or suspected novel coronavirus infection (manifesting symptoms such as fever, headache, fatigue, joint pain, runny nose, sore throat, and persistent cough, and the disease course is consistent with the prevalent strain).
  • Subjects selected within 4 weeks before having a history of invasive or non-invasive mechanical ventilation.
  • Subjects selected during the screening who have active pulmonary tuberculosis, poorly controlled bronchial asthma, acute pulmonary embolism, severe pulmonary hypertension [cardiac ultrasound examination > 70 mmHg], etc.
  • Subjects selected within 6 months before having a serious non-pulmonary systemic disease and judged by the researcher as not suitable to participate in this study, such as diabetes with ketoacidosis or hyperosmolar coma, acute myocardial infarction, unstable angina pectoris, heart failure grade III/IV, stroke, liver cirrhosis with severe liver dysfunction, severe renal insufficiency, etc.
  • Subjects selected during the screening who have severe anemia, or controlled poorly granulocytopenia or thrombocytopenia.
  • Subjects selected during the screening who have a history of suicide risk, psychiatric history or epilepsy history.
  • Subjects selected during the screening who have severe malnutrition.
  • Subjects selected during the screening whose 12-lead shows severe arrhythmias (such as ventricular tachycardia, supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or second-degree and above conduction abnormalities of the heart.
  • Subjects selected within 4 weeks before participating in other clinical trials with intervention measures or using other biological agents for treatment.
  • Researchers, collaborating researchers, research coordinators, researchers participating in the study or employees of the research center or their family members.
  • Subjects selected during the screening who the researcher considers unsuitable to participate in the trial (increasing the risk for the subjects or interfering with the clinical trial).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    REGEND007 Cell Therapy

    Biological: REGEND007 Cell Therapy

Interventions

  • BiologicalREGEND007 Cell Therapy

    This study's intravenous infusion dose escalation protocol is based on a 3+3 dose escalation design, with a total of 4 dose groups. Each group included 3 subjects, and the dose is gradually increased until the maximum tolerated dose(MTD) or the maximum administered dose (MAD) is reached.

06

What researchers measure

Primary outcomes

  1. The incidence and severity of drug-related adverse events (AEs)

    All adverse medical events that occur from the time the subject signs the informed consent form. These can manifest as symptoms, signs, diseases, or abnormal laboratory test results, but they do not necessarily have a causal relationship with the investigational drug.

    Time frame: 12 weeks after the administration

Secondary outcomes

  1. The change in the actual forced vital capacity (FVC) compared to the baseline

    FVC is the full amount of air that can be-exhaled with effort in a complete breath

    Time frame: 24 hours after administration, 4 and 12 weeks after the last administration

  2. The change in forced vital capacity (FVC) actual-to-predicted ratio compared to the baseline

    The FVC actual-to-predicted ratio is a crucial indicator in pulmonary function tests, and it is mainly used to determine whether there is restrictive ventilation dysfunction.

    Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.

  3. The change in the actual forced expiratory volume in one second (FEV1) compared to the baseline

    FEV1 is the volume of breath exhaled with effort in one second.

    Time frame: 24 hours after administration, 4 and 12 weeks after the last administration

  4. The change in the forced expiratory volume in one second (FEV1) actual-to-predicted ratio compared to the baseline

    The FEV1 actual-to-predicted ratio is a crucial indicator in pulmonary function tests, representing the percentage relationship between the actual measured value of the first-second forced expiratory volume (FEV1) and the predicted value calculated based on individual characteristics. Under normal circumstances, the actual measured value of FEV1 should reach more than 80% of the predicted value.

    Time frame: 24 hours after administration, 4 and 12 weeks after the last administration

  5. The change in the carbon monoxide diffusion capacity (DLCO) compared to the baseline

    DLCO is a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.

    Time frame: 24 hours after administration, 4 and 12 weeks after the last administration

  6. The change in carbon monoxide diffusion capacity (DLCO) actual-to-predicted ratio compared to the baseline

    DLCO actual-to-predicted ratio is a crucial indicator in pulmonary function testing, used to assess the oxygen exchange capacity and efficiency of the alveoli.

    Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.

  7. The change in the ratio of carbon monoxide diffusion capacity to lung alveolar volume (DLCO/VA) compared to the baseline

    DLCO/VA is also known as the diffusion constant, since the diffusion amount is affected by the alveolar ventilation volume, a decrease in alveolar ventilation volume can lead to a reduction in DLCO. Therefore, this value is often used for correction to eliminate the influence of lung volume on the diffusion amount.

    Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.

  8. The change in the six-minute walk test (6MWT) compared to the baseline

    6MWT is one of the commonly used methods in clinical practice for assessing a patient's cardiac and pulmonary functions, which involves measuring the distance that a patient can walk quickly on a flat and hard surface within 6 minutes.

    Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.

  9. The time when the first acute exacerbation of IPF occurred after administration

    The time when the first acute exacerbation of IPF occurred after administration is helpful for assessing disease progression and prognosis.

    Time frame: Within 12 weeks after administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 12 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 22, 2026
StartEst.
Feb 15, 2026
Primary completionEst.
Feb 15, 2027
CompletionEst.
Jun 15, 2027
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359963
Lead sponsor
Regend Therapeutics
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Feb 15, 2026 (estimated)
Primary completion
Feb 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Jan 22, 2026

Study contacts

Kai Wang, Professor and Chief Physician
Contact
kaiw@zju.edu.cn
086-0579-89935016

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion